uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
November 06 2019 - 9:16AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe unmet
medical needs, today announced that six data presentations will be
delivered at the 61st American Society of Hematology (ASH) Annual
Meeting, taking place in Orlando, Florida.
“We are looking forward to our strong presence
at ASH next month,” stated Matt Kapusta, chief executive officer at
uniQure. “The breadth of data to be presented at ASH this year
represents the continued development of uniQure’s industry-leading
gene therapy platform and expertise in the hemophilia
field.”
Investor and Analyst Breakfast and
Webcast
uniQure management will host an investor &
analyst breakfast featuring Steven Pipe, M.D., professor of
pediatrics and pathology and pediatric medical director of the
hemophilia and coagulation disorders program at the University of
Michigan, (AMT-061), who will review the 12-month follow-up data on
etranacogene dezaparvovec (AMT-061) presented at ASH. The investor
& analyst breakfast will take place on Monday, December 9, from
7:00 a.m. to 8:00 a.m. ET, at the Hilton Orlando, Florida.
The meeting will be webcast live along with
slides and can be accessed by visiting the investor relations
section of the Company’s website at www.uniQure.com
To request attendance at the meeting, please
RSVP to Investors@uniQure.com by November 30, 2019, as space is
limited.
Specific details on uniQure’s presentations at
ASH include:
Title: |
One Year Data
from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an
Enhanced Vector for Gene Transfer in Adults with Severe or
Moderate-Severe Hemophilia B |
Session Name: |
801. Gene Therapy and Transfer: Poster II |
Date: |
Sunday, December 8, 2019 |
Presentation Time: |
6:00 - 8:00 p.m. ET |
Location: |
Orange County Convention Center, Hall B |
|
|
Title: |
Stable FIX Expression and Durable Reductions in Bleeding and
Factor IX Consumption for up to 4 Years Following AMT-060 Gene
Therapy in Adults with Severe or Moderate-Severe Hemophilia B |
Session Name: |
801. Gene Therapy and Transfer: Poster I |
Date: |
Saturday, December 7, 2019 |
Presentation Time: |
5:30 - 7:30 p.m. ET |
Location: |
Orange County Convention Center, Hall B |
|
|
Title: |
Seroprevalence of Pre-Existing Nabs Against AAV1, 2, 5, 6 and 8
in South African Hemophilia B Patient Population |
Session Name: |
801. Gene Therapy and Transfer: Poster II |
Date: |
Sunday, December 8, 2019 |
Presentation Time: |
6:00 - 8:00 p.m. ET |
Location: |
Orange County Convention Center, Hall B |
|
|
Title: |
Evaluation of a Blood Coagulation Factor IX Variant that
Functions Independently of Factor VIII as an Alternative Treatment
of Hemophilia A |
Session Name: |
321. Blood Coagulation and Fibrinolytic Factors: Poster I |
Date: |
Saturday, December 7, 2019 |
Presentation Time: |
5:30 - 7:30 p.m. ET |
Location: |
Orange County Convention Center, Hall B |
|
|
Title: |
Prophylactic Treatment in People with Severe Hemophilia B in
the US: An Analysis of Real-World Healthcare System Costs and
Clinical Outcomes |
Session Name: |
901. Health Services Research—Non-Malignant Conditions: Poster
I |
Date: |
Saturday, December 7, 2019 |
Presentation Time: |
5:30 - 7:30 p.m. ET |
Location: |
Orange County Convention Center, Hall B |
|
|
Title: |
Clearance of Vector DNA Following Systemic Administration of
AAV5-hFIX or AAV5-hFIX Padua in Patients with Severe or
Moderate-Severe Hemophilia B |
Session Name: |
801. Gene Therapy and Transfer: Poster I |
Date: |
Saturday, December 7, 2019 |
Presentation Time: |
5:30 - 7:30 p.m. ET |
Location: |
Orange County Convention Center, Hall B |
The conference abstracts were made available today and can be
accessed through this link: ASH abstracts.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. We
are leveraging our modular and validated technology platform to
rapidly advance a pipeline of proprietary gene therapies to treat
patients with hemophilia B, hemophilia A, Huntington's disease,
Fabry disease, spinocerebellar ataxia Type 3 and other
diseases. www.uniQure.com
uniQure Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, the ability of
etranacogene dezaparvovec to be a first-in-class or best-in-class
gene therapy for patients with hemophilia B, the ability to add up
to six additional patients before the end of September 2019, and
whether top-line data from the Phase III trial can be shared next
year or ever. Our actual results could differ materially from those
anticipated in these forward-looking statements for many reasons,
including, without limitation, risks associated with our and our
collaborators’ clinical development activities, clinical results,
collaboration arrangements, corporate reorganizations and strategic
shifts, regulatory oversight, product commercialization and
intellectual property claims, as well as the risks, uncertainties
and other factors described under the heading "Risk Factors" in
uniQure’s Quarterly Report on Form 10-Q filed on July 29, 2019.
Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements,
even if new information becomes available in the future.
uniQure Contacts:
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: +31 6 52 33 15 79 |
Mobile: 339-223-8541 |
m.cantor@uniQure.com |
e.mulder@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024